ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023
/PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global
biotechnology company focused on bringing highly differentiated
medicines to patients around the world through the discovery,
development, and commercialization of novel immunotherapies and
biologics, today announced that two poster presentations featuring
preclinical data on givastomig (also known as TJ-CD4B/ABL111) and
TJ-L14B/ABL503, the Company's 4-1BB-targeting bispecific antibody
assets, will be reported at the 38th Society for
Immunotherapy of Cancer's (SITC) Annual Meeting, taking place
November 1-5, 2023, in San Diego, California.
The full text of the abstracts has been released on the SITC
website, and the posters will be available on the Company's website
following the conclusion of SITC 2023. Details of the poster
presentations are as follows:
Title:
|
Givastomig, a novel
Claudin18.2/4-1BB bispecific antibody, exerts bystander
tumor-killing and synergistic anti-tumor activity with therapeutics
in 1L/2L treatment for gastric cancer
|
Poster #:
|
792
|
Presenter:
|
Dr. Xuejun Liu,
I-Mab
|
Date/Time:
|
Saturday, November 4,
2023
9:00 a.m. – 8:30 p.m.
Pacific Time (12:00
p.m.
– 11:30 p.m.
Eastern Time)
|
Full
abstract
|
https://jitc.bmj.com/content/11/Suppl_1/889
|
Title:
|
ABL503 (TJ-L14B),
PD-L1×4-1BB bispecific antibody, reinvigorates exhausted
tumor-infiltrating CD8+ T cells and synergizes with PD-1
blockade
|
Abstract ID:
|
845
|
Presenter:
|
Dr. Jaeho Jung, ABL
Bio
|
Date/Time:
|
Friday, November 3,
2023
9:00 a.m. – 7:00 p.m.
Pacific Time (12:00
p.m.
– 10:00 p.m. Eastern Time)
|
Full
abstract
|
https://jitc.bmj.com/content/11/Suppl_1/944
|
About Givastomig
Givastomig, also known as TJ-CD4B/ABL111, is a bispecific
antibody designed to bind to Claudin 18.2 (CLDN18.2) as a tumor
engager and 4-1BB as a conditional T-Cell activator. It binds to
tumor cells expressing various levels of CLDN18.2, i.e., gastric
cancer and pancreatic cancer cells, and conditionally activates
intra-tumoral T cells at the tumor site through the 4-1BB arm.
Givastomig appears to effectively maintain a strong tumor binding
property and anti-tumor activity attributable to a synergistic
effect of both CLDN18.2 antibody and 4-1BB antibody while avoiding
or minimizing liver toxicity and systemic immunotoxicity commonly
seen with 4-1BB antibodies as a drug class. Being developed under
collaboration between I-Mab and ABL Bio, a clinical-stage
biotechnology company in South
Korea, givastomig is currently being investigated in a Phase
1 clinical study in the U.S. and China. In March
2022, the U.S. Food and Drug Administration (FDA) granted
Orphan Drug Designation for givastomig for the treatment of gastric
cancer, including cancer of the gastroesophageal junction.
About TJ-L14B/ABL503
Being developed jointly with ABL Bio (Kosdaq: 298380, hereafter
"ABL"), TJ-L14B/ABL503 is a differentiated PD-L1-based bispecific
antibody with the PD-L1 arm as the tumor-dependent T-cell activator
and the 4-1BB arm as the conditional T cell activator upon tumor
engagement. Using ABL's "Grabody-T" bispecific antibody platform
technology, TJ-L14B/ABL503 stimulates 4-1BB activation only in the
presence of PD-L1 expressing tumor cells to minimize the risk of
off-tumor toxicity. Preclinical studies have demonstrated that the
bispecific antibody shows better anti-tumor activity than equimolar
doses of single agents alone or in combination. A Phase 1 study is
currently being conducted in the U.S. and South Korea.
About I-Mab
I-Mab (Nasdaq: IMAB) is a global biotechnology
company focused on bringing highly differentiated medicines to
patients around the world through the discovery, development, and
commercialization of novel immunotherapies and
biologics. I-Mab's innovative pipeline is driven by
internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market
development strategies, and through global partnerships. For
more information, please
visit https://www.i-mabbiopharma.com and follow us
on LinkedIn, Twitter, and WeChat.
I-Mab Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
data from clinical studies of givastomig or TJ-L14B, the potential
implications of clinical data for patients, and I-Mab's advancement
of, and anticipated clinical development, regulatory milestones,
and commercialization of givastomig or TJ-L14B. Actual results may
differ materially from those indicated in the forward-looking
statements as a result of various important factors, including but
not limited to I-Mab's ability to demonstrate the safety and
efficacy of its drug candidates; the clinical results for its drug
candidates, which may not support further development or NDA/BLA
approval; the content and timing of decisions made by the relevant
regulatory authorities regarding regulatory approval of I-Mab's
drug candidates; I-Mab's ability to achieve commercial success for
its drug candidates, if approved; I-Mab's ability to obtain and
maintain protection of intellectual property for its technology and
drugs; I-Mab's reliance on third parties to conduct drug
development, manufacturing and other services; I-Mab's limited
operating history and I-Mab's ability to obtain additional funding
for operations and to complete the development and
commercialization of its drug candidates; and the impact of the
COVID-19 pandemic on the Company's clinical development, commercial
and other operations, as well as those risks more fully discussed
in the "Risk Factors" section in I-Mab's most recent annual report
on Form 20-F, as well as discussions of potential risks,
uncertainties, and other important factors in I-Mab's subsequent
filings with the US Securities and Exchange Commission. All
forward-looking statements are based on information currently
available to I-Mab, and I-Mab undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required by law.
I-Mab Contacts
Investors
|
Media
|
Tyler Ehler
|
Gigi Feng
|
Senior Director,
Investor Relations
|
Chief Communications
Officer
|
IR@i-mabbiopharma.com
|
PR@i-mabbiopharma.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/i-mab-announces-poster-presentations-of-4-1bb-bispecific-antibody-portfolio-at-sitc-2023-301973914.html
SOURCE I-Mab